Market Flash on Regencell Bioscience (RGC)

EquiLend Data & Analytics identifies Regencell Bioscience as a prime short squeeze candidate, with its short squeeze score at 88. With utilization approaching 86% and extremely elevated borrow fees of 60,000 BPS, short sellers are facing mounting pressure as positive clinical trial results for ADHD and ASD treatments drive momentum. This $1.2B biotech powerhouse has seen its short squeeze score surge from 21 to 88 in just one week, potentially triggering a significant short covering rally in the coming days.

Company Overview

Regencell Bioscience Holdings Ltd. is a biopharmaceutical company focused on the research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders including ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder). Founded in Hong Kong and now headquartered in the United States, the company combines traditional healing methodologies with modern scientific validation to create standardized treatment protocols. Regencell’s approach centers on personalized formulations of natural herbs and compounds, tailored to individual patient profiles.

Note: Data as of May 6, 2025. EquiLend Short Squeeze Score ranges from 0-100, with higher scores indicating greater likelihood of a short squeeze.

Catalyst

Regencell Bioscience recently announced promising results from its second efficacy trial for ADHD and ASD using standardized Traditional Chinese Medicine protocols. The trial demonstrated statistically significant improvements in core symptoms compared to placebo, with a favorable safety profile. This breakthrough has significantly increased investor interest, as it represents one of the first successful applications of TCM in addressing these widespread neurodevelopmental conditions through rigorous clinical validation. Additionally, insider confidence is evident with substantial share purchases by executives, including CEO Yat-Gai Au, further supporting positive market sentiment.

Market Implications

The positive clinical trial results come at a time when the market for ADHD and ASD treatments is experiencing rapid growth, with increasing diagnosis rates and limited effective treatment options. If Regencell’s TCM-based approach continues to demonstrate efficacy in larger trials, it could potentially disrupt the current treatment paradigm dominated by pharmaceutical stimulants and behavioral therapies. The company’s unique positioning at the intersection of traditional medicine and modern neuroscience creates a compelling narrative for investors seeking exposure to innovative healthcare solutions. However, the dramatic price increase has attracted significant short interest, setting up conditions for a potential short squeeze.

Squeeze Analysis

Regencell Bioscience (RGC) currently has a short squeeze score of 88. Our proprietary EquiLend Short Squeeze Score metric, which ranges from 0 to 100, measures the likelihood of a potential short squeeze by analyzing factors such as short interest, borrowing costs and price momentum. The score has seen a dramatic increase from 21 just one week ago to 88 today, indicating rapidly growing pressure on short sellers.

The stock’s utilization rate of 86% is approaching critical levels, suggesting that available shares for borrowing are becoming scarce. This high utilization is accompanied by an extraordinary borrowing fee of 60,000 BPS (600% annualized). These securities lending metrics indicate supply constraints and significant costs for maintaining short positions.

The combination of positive clinical trial results, insider buying, and deteriorating securities lending metrics creates ideal conditions for a potential short squeeze. As the stock price continues to rise, short sellers may be forced to cover their positions, further accelerating the upward price movement in a self-reinforcing cycle.

Technical Analysis

Regencell Bioscience’s stock has broken above all major moving averages, confirming a strong bullish trend. The recent price surge has been accompanied by significantly above-average trading volume, indicating strong conviction among buyers.

Key resistance levels have been decisively broken, with the stock making new all-time highs. The price action shows a series of higher highs and higher lows, a classic sign of a strong uptrend. While the rapid ascent may lead to increased volatility in the near term, the technical picture remains overwhelmingly bullish, supported by both fundamental catalysts and deteriorating securities lending metrics.

Conclusion

Regencell Bioscience (RGC) presents a compelling short squeeze possibility due to its short squeeze score of 88, extremely elevated borrowing fee of 60,000 BPS, high utilization rate of 86%, and recent positive clinical trial results serving as a catalyst.

The combination of fundamental catalysts, technical breakout, and deteriorating securities lending metrics suggests that short sellers are under significant pressure. The dramatic increase in short squeeze score from 21 to 88 in just one week indicates rapidly accelerating pressure that could trigger a substantial short covering rally.

Traders should monitor RGC closely, particularly for increases in trading volume and acceleration in price movement, which could signal the beginning of a more pronounced squeeze. However, given the stock’s recent volatility and momentum, position sizing and risk management remain crucial considerations.

Contact us at https://equilend.com/services/equilend-short-squeeze-score/ to find out how you can leverage EquiLend’s Short Squeeze Score today.

Bloomberg Terminal users can subscribe to EquiLend’s exclusive Orbisa securities lending data by entering terminal shortcut APPS ORBISA <GO> or clicking the following link: https://on.equilend.com/bloomberg-terminal-page